Abstract
Pathological retinal neovascularization (RNV) is a common microvascular complication in several retinal diseases including retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration and central vein occlusion. The current therapeutic modalities of RNV are invasive and although they may slow or halt the progression of the disease, they are unlikely to restore normal acuity. Therefore, there is an urgent need to develop treatment modalities that are less invasive and thus associated with fewer procedural complications and systemic side effects. This review article summarizes our understanding of the pathophysiology and current treatment of RNV in ischemic retinopathies, lists potential therapeutic targets and provides a framework for the development of future treatment modalities.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 267-286 |
| Number of pages | 20 |
| Journal | Expert Review of Ophthalmology |
| Volume | 8 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- PEDF
- PPAR
- VEGF
- inflammation
- lipoxygenase
- oxidative stress
- retinal neovascularization
- retinopathy
ASJC Scopus subject areas
- Biomedical Engineering
- Ophthalmology
- Optometry
Fingerprint
Dive into the research topics of 'Targeting neovascularization in ischemic retinopathy: Recent advances'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS